Antitumor effect of locally produced CD95 ligand

被引:0
|
作者
Ken-Ichiro Seino
Nobuhiko Kayagaki
Ko Okumura
Hideo Yagita
机构
[1] Juntendo University School of Medicine,Department of Immunology
[2] University ofTsukuba School of Medicine,Department of Surgery
[3] Tsukuba Science City,undefined
[4] CREST,undefined
[5] Japan Science and Technology Corporation (JST),undefined
来源
Nature Medicine | 1997年 / 3卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Activation of the cell-surface antigen CD95 induces apoptosis of CD95-bearing tumor cells. In this study, we investigated the antitumor effect of locally produced CD95 ligand (CD95L) on CD95-negative tumor cells in vivo. Introduction of CD95L cDNA into murine tumor cells did not affect growth in vitro but caused rejection in vivo. Neutrophils were primarily responsible for this rejection. A CD8+ T cell-mediated protective immunity against subsequent challenge with parental tumor cells was also elicited. These results provide evidence for the potential utility of CD95L in tumor eradication and also reveal a proinflammatory function of CD95L.
引用
收藏
页码:165 / 170
页数:5
相关论文
共 50 条
  • [21] Differences between CD95 type I and type II cells detected with the CD95 ligand
    Schmitz, I
    Walczak, H
    Krammer, PH
    Peter, ME
    CELL DEATH AND DIFFERENTIATION, 1999, 6 (09): : 821 - 822
  • [22] Role of apoptosis and CD95/CD95 ligand expression in chronic hepatitis C and HIV infection
    Filipowicz, E
    Otolade, O
    Xiao, SY
    Adegboyega, PA
    MODERN PATHOLOGY, 2001, 14 (01) : 196A - 196A
  • [23] The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis
    Manlio Tolomeo
    Luisa Dusonchet
    Maria Meli
    Stefania Grimaudo
    Natale D'Alessandro
    Giuliana Papoff
    Giovina Ruberti
    Luciano Rausa
    Cell Death & Differentiation, 1998, 5 : 735 - 742
  • [24] Role of apoptosis and CD95/CD95 ligand expression in chronic hepatitis C and HIV infection
    Filipowicz, E
    Ololade, O
    Xiao, SY
    Adeboyega, PA
    LABORATORY INVESTIGATION, 2001, 81 (01) : 196A - 196A
  • [25] Evaluation of CD95 (APO-1/FAS) and the CD95 ligand in acute myelogenous leukemia
    Mestice, A
    Specchia, G
    Coppi, MR
    Palumbo, G
    Carluccio, P
    Attolico, I
    Quarta, A
    Liso, V
    EXPERIMENTAL HEMATOLOGY, 1997, 25 (08) : 74 - 74
  • [26] The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis
    Tolomeo, M
    Dusonchet, L
    Meli, M
    Grimaudo, S
    D'Alessandro, N
    Papoff, G
    Ruberti, G
    Rausa, L
    CELL DEATH AND DIFFERENTIATION, 1998, 5 (09): : 735 - 742
  • [27] Synergy of CD95 ligand and teniposide: No role of cleavable complex formation and enhanced CD95 expression
    Winter, S
    Roth, W
    Dichgans, J
    Weller, M
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 341 (2-3) : 323 - 328
  • [28] CD95-ligand and hyperosmolarity trigger CD95/EGF receptor association and tyrosine phosphorylation of CD95 as prerequisites for CD95 membrane trafficking and disc formation.
    Reinehr, R
    Schliess, F
    Häussinger, D
    HEPATOLOGY, 2003, 38 (04) : 570A - 570A
  • [29] CD95-tyrosine nitration inhibits hyperosmotic and CD95 ligand-induced CD95 activation in rat hepatocytes
    Reinehr, R
    Görg, B
    Höngen, A
    Häussinger, D
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (11) : 10364 - 10373
  • [30] Dysregulation of CD95/CD95 ligand apoptotic pathway in CD3+ large granular lymphocyte leukemia
    Lamy, T
    Liu, JH
    Landowski, TH
    Dalton, WS
    Loughran, TP
    BLOOD, 1998, 92 (12) : 4771 - 4777